George Simeon

10% Owner | Director

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001595117

Purchase history

Companies traded: 5
Purchases · 12M: 3
Purchases · 24M: 5
Average purchase: $18.2M
Median purchase: $10.0M
Gross purchase value: $91.0M

Companies: ADARx Pharmaceuticals, Inc. | Avalyn Pharma Inc. | CRISPR Therapeutics AG | Odyssey Therapeutics, Inc. | Zenas BioPharma, Inc.

5 SEC accession(s) · 3 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

Published	Company	Ticker	Role	Reported value	SEC source
2026-09-29	ADARx Pharmaceuticals, Inc.	ADRX	Director \| 10% Owner	$17.1M	Open filing
2026-05-11	Odyssey Therapeutics, Inc.	ODTX	10% Owner	$10.0M	Open filing
2026-05-01	Avalyn Pharma Inc.	AVLN	10% Owner	$10.0M	Open filing
2025-10-14	Zenas BioPharma, Inc.	ZBIO	10% Owner	$2.4M	Open filing
2025-07-17	CRISPR Therapeutics AG	CRSP	Director	$51.5M	Open filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	3Small Sample	60.0% (3/5)	0.0% (0/3)	-10.8%	-7.7%	-11.9%
20D	2Small Sample	50.0% (2/4)	0.0% (0/2)	-8.8%	-8.8%	-15.9%
60D	2Small Sample	50.0% (2/4)	50.0% (1/2)	+6.0%	+6.0%	-7.3%
120D	0No Data	0.0% (0/2)	—	—	—	—

Research patterns

First purchase in 12M: 3/3
Large purchase ≥ $100k: 5/5
Cluster buying · 15D: 4/5
Buying the dip: 0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.